This article provides a comprehensive medical overview of rare diseases, with a dual focus: first, on drug-induced rare diseases as adverse reactions, and second, on the critical risk-benefit calculus for therapies where the treatment's side effects may be as severe as the disease itself.
Medical overview of childhood cancer, with special emphasis on drug-induced adverse reactions, including the rarely discussed topic of therapy-related secondary cancers, and their management from a pharmacovigilance perspective.
From a pharmacovigilance standpoint, drug-induced anaemia is a significant and often under-recognized adverse drug reaction (ADR). It can occur through various mechanisms, and early detection is crucial to prevent morbidity and mortality.
The era of one-size-fits-all medicine is rapidly giving way to a more precise, personalized approach, thanks to the field of pharmacogenomics (PGx). Pharmacogenomics, a cornerstone of personalized medicine, studies how an individual's genetic makeup influences their response to medications.
Vaccine safety refers to the scientific and medical standards applied to ensure vaccines are as free from risk as possible while providing significant protection against infectious diseases.
Hemodialysis vascular access is often termed the “lifeline” of patients with end-stage renal disease. However, due to frequent complications, it is also considered the “Achilles heel” of hemodialysis therapy. While traditional patient safety efforts have focused on clinician training and patient education, this chapter advocates for a transformative approach—one that prioritizes individualization of care and active...
In the realm of patient safety, the spotlight often shines on pharmacovigilance—the science of monitoring drug side effects. However, a parallel and equally critical discipline operates in the shadows: Medical Device Vigilance.
Advancing Medication Safety Through Knowledge and Vigilance
